Your session is about to expire
← Back to Search
Niraparib + Dostarlimab for Pancreatic Cancer
Study Summary
This trial studies niraparib and dostarlimab as a treatment for pancreatic cancer that has spread to other places in the body and has mutations in the BRCA1/2 or PALB2 gene.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 37 Patients • NCT03207347Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have stomach or intestine problems affecting medicine absorption.I am still recovering from side effects or complications of my last surgery or treatment.I have not had a blood transfusion or received growth factors in the last 4 weeks.I have severe anemia, low white blood cell count, or low platelet count from past chemotherapy.I have not received any live vaccines in the last 30 days and do not plan to during the study.I do not have any uncontrolled illnesses or mental health issues.I have been treated with PARP inhibitors and immunotherapy together.My diagnosis of pancreatic cancer was confirmed through tissue or cell testing.I have brain metastases, uncontrolled seizures, or an active neurological condition.I have had 1 or 2 treatments for my cancer that has spread.I have had a bone marrow transplant or intense chemotherapy needing stem cell support.I have a history of myelodysplastic syndrome or acute myeloid leukemia.I have a condition that weakens my immune system.I am not using or cannot use birth control.You are expected to live for at least 3 more months.I am fully active or can carry out light work.You have a disease that can be measured or evaluated according to iRECIST guidelines.I had severe side effects from previous immunotherapy.I have recently undergone radiotherapy or radionuclide treatment.I am willing to have more biopsies if needed.I do not have any serious bacterial infections.I had cancer treatment within the last 2 years before this study.I have a harmful genetic mutation identified in my test results.I have active hepatitis B or C.I have or had tuberculosis.I have an active or suspected unstable autoimmune disease.I have received platinum-based chemotherapy as an initial or follow-up treatment.Your blood test results for certain levels (like kidney function, red blood cells, white blood cells, and liver function) need to be within a certain range.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Treatment (niraparib, dostarlimab)
Frequently Asked Questions
How many guinea pigs are participating in this test?
"That is correct. The clinical trial, which was posted on December 28th 2020, appears to be recruiting patients based on the information available from clinicaltrials.gov . 20 individuals are required for this study that will take place across 3 medical facilities."
What are the main indications for Niraparib?
"Niraparib shows efficacy in treating primary peritoneal cancer, as well as advanced endometrial cancer for patients who have not responded to platinum-based chemotherapy. Additionally, this medication can be used to treat fallopian tube cancer."
What are some of the risks associated with taking Niraparib?
"Niraparib is at a Phase 2 level, so there is only some data supporting its safety. This score of 2 reflects that lack of evidence for efficacy."
Is Niraparib a common drug to test in medical research?
"Niraparib is being investigated in 112 different clinical trials, 14 of which are Phase 3. Most of these studies are located in Washington D.C., though there are 3147 total locations for these Niraparib trials."
Are patients currently able to sign up for this clinical trial?
"Yes, this trial is still looking for patients. 28 December 2020 was when the listing was first created and it has been updated as recently as 20 September 2022."
Share this study with friends
Copy Link
Messenger